Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionQuarry LP
Latest Disclosed Ownership13,870 shares
Latest Disclosed Value $ 412,078
Quarry LP ownership in TVTX / Travere Therapeutics, Inc.

On May 15, 2026 - Quarry LP filed a 13F-HR form disclosing ownership of 13,870 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $412,078 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 0 shares of Travere Therapeutics, Inc.. The current value of the position is $626,924 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 13,870 13,870 412 0.0739
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 0 -14,960 -100.00 0 -100.00
2025-11-14 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 14,960 7,960 113.71 358 246.60 0.0784
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 7,000 -8,000 -53.33 104 -61.57 0.0220
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 15,000 3,000 25.00 269 28.23 0.0583
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 12,000 4,500 60.00 209 100.96 0.0294
2024-11-14 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 7,500 7,500 105 0.0264
2024-08-16 2024-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 0 -10,000 -100.00 0 -100.00
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 0 0
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 10,000 5,500 122.22 77 92.50 0.0147
2024-02-20 2023-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 4,500 -5,500 -55.00 40 -55.06 0.0062
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,500 -5,500 40 0.0058
2023-11-14 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 10,000 10,000 89 0.0208
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.